Remus Pharmaceuticals Limited
ListedSMEPharmaceuticals & Healthcare · NSE
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.
Price Band
₹1150 – ₹1229
Issue Size
₹47.69 Cr
Lot Size
100 shares
GMP
₹470
+38.2%
Est. Listing
₹1699
at current GMP
Subscribed
61.53x
overall
Open
17 May 2023
Close
19 May 2023
Allotment
24 May 2023
Refund
25 May 2023
Demat Credit
26 May 2023
Listing
29 May 2023
Last updated 12 days ago
Overall Subscription
61.53x
Total Demand
QIB Multiplier
20.24x
Institutions & Funds
NII / HNI
172.60x
High Net-Worth
Retail (RII)
37.50x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 73,700 | 1,492,000 | 20.24x |
| NIB | 55,300 | 9,545,000 | 172.60x |
| RETAIL | 129,000 | 4,837,600 | 37.50x |
| Total | 258,000 | 15,874,600 | 61.53x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| Retail (RII) | 1,358 | 50,925 | 37.50x |
| HNIs (10L +) | 9 | 1,553 | 172.60x |
| HNIs (2-10L) | 42 | 7,249 | 172.60x |
| Total Applications | 1,409 | 59,727 | 42.39x |
Day-Wise Subscription Progress
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.